Latest Articles
Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline - Investing.com UK
Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline Investing.com UK
Published: May 21, 2026, 8:34 p.m.
Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline - Investing.com
Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline Investing.com
Published: May 21, 2026, 2:57 p.m.
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - BioSpace
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update BioSpace
Published: May 18, 2026, 1:17 a.m.
Maipl Therapeutics Advances Non-Hormonal Oral Endometriosis Therapy Targeting Prostaglandin F2α Receptor - Femtech Insider
Maipl Therapeutics Advances Non-Hormonal Oral Endometriosis Therapy Targeting Prostaglandin F2α Receptor Femtech Insider
Published: May 15, 2026, 11:33 a.m.
Karyopharm Therapeutics Reports Q1 2026 Results, Advances Selinexor Phase 3 Trials in Myelofibrosis and Endometrial Cancer - Minichart
Karyopharm Therapeutics Reports Q1 2026 Results, Advances Selinexor Phase 3 Trials in Myelofibrosis and Endometrial Cancer Minichart
Published: May 14, 2026, 4:30 p.m.
Maipl Therapeutics Reports Preclinical Progress for MA-4604, a Novel Oral Non-Hormonal Treatment of Endometriosis - Newswise
Maipl Therapeutics Reports Preclinical Progress for MA-4604, a Novel Oral Non-Hormonal Treatment of Endometriosis Newswise
Published: May 14, 2026, 12:40 p.m.
Karyopharm Therapeutics stock (US48576U1060): Q1 revenue beats estimates, trial enrollment complete - AD HOC NEWS
Karyopharm Therapeutics stock (US48576U1060): Q1 revenue beats estimates, trial enrollment complete AD HOC NEWS
Published: May 14, 2026, 12:26 p.m.
Endometriosis Therapeutics Market to Reach US$ 4.05 Billion - openPR.com
Endometriosis Therapeutics Market to Reach US$ 4.05 Billion openPR.com
Published: May 5, 2026, 7:37 a.m.
Emerging Sub-Segments Transforming the Digital Therapeutics Market for Endometriosis - openPR.com
Emerging Sub-Segments Transforming the Digital Therapeutics Market for Endometriosis openPR.com
Published: May 1, 2026, 1:36 p.m.
Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as Highly Expressed, Clinically Relevant Target for Gynecologic Cancers - National Today
Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as Highly Expressed, Clinically Relevant Target for Gynecologic Cancers National Today
Published: April 10, 2026, 4:35 p.m.
Link copied to clipboard!